Skip to main content

Table 3 Univariate analysis of factors influencing the survival time of breast cancer patients with second primary malignancy

From: Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China

Variables

OSa

CSSa

OS: SPMb

CSS: SPMb

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

HR (95% CI)

p

Age at BC diagnosis (years)

≥ 56 versus < 56

1.68 (1.06–2.67)

0.027

1.64 (1.03–2.60)

0.038

2.00 (1.26–3.16)

0.003

1.95 (1.22–3.10)

0.005

Age at SPM diagnosis (years)

 ≥ 62 versus < 62

1.43 (0.90–2.27)

0.126

1.40 (0.88–2.22)

0.156

2.15 (1.35–3.42)

0.001

2.10 (1.32–3.35)

0.002

TNM stage of BC

I + II (ref)

        

III + IV

1.29 (0.58–2.85)

0.530

1.32 (0.60–2.92)

0.498

1.57 (0.71–3.47)

0.261

1.61 (0.73–3.55)

0.241

Unclassified

1.05 (0.60–1.84)

0.869

1.07 (0.61–1.88)

0.816

1.24 (0.71–2.19)

0.445

1.27 (0.72–2.24)

0.404

TNM stage of SPM

I + II (ref)

        

III + IV

5.08 (2.38–10.84)

 < 0.001

5.07 (2.38–10.83)

 < 0.001

7.13 (3.33–15.28)

 < 0.001

7.17 (3.34–15.36)

 < 0.001

Unclassified

5.03 (2.44–10.40)

 < 0.001

4.90 (2.37–10.14)

 < 0.001

5.65 (2.72–11.74)

 < 0.001

5.53 (2.66–11.50)

 < 0.001

BC therapeutic hospital grade

Secondary versus tertiary

0.82 (0.50–1.33)

0.412

0.78 (0.48–1.28)

0.328

0.72 (0.44–1.18)

0.195

0.69 (0.42–1.14)

0.146

SPM therapeutic hospital grade

Secondary versus tertiary

1.40 (0.86–2.29)

0.181

1.34 (0.81–2.21)

0.251

1.78 (1.08–2.93)

0.024

1.70 (1.02–2.83)

0.040

Surgery for BC

No (ref)

        

Yes

1.24 (0.74–2.10)

0.419

1.29 (0.76–2.20)

0.340

1.02 (0.61–1.73)

0.929

1.07 (0.63–1.82)

0.806

Unknown

0.68 (0.34–1.37)

0.280

0.71 (0.35–1.43)

0.337

1.64 (0.87–3.09)

0.127

1.71 (0.90–3.24)

0.100

Surgery for SPM

Yes versus No

0.40 (0.25–0.65)

 < 0.001

0.41 (0.25–0.66)

 < 0.001

0.36 (0.22–0.57)

 < 0.001

0.36 (0.22–0.59)

 < 0.001

SPM sites

Colon and rectum

  No versus yes

1.77 (0.91–3.45)

0.094

1.74 (0.89–3.40)

0.104

1.52 (0.80–2.88)

0.202

1.50 (0.79–2.84)

0.219

Thyroid

  No versus yes

11.92 (1.66–85.84)

0.014

11.77 (1.63–84.80)

0.014

20.65 (2.87–148.69)

0.003

20.44 (2.84–147.20)

0.003

Lung and bronchus

  No versus yes

0.90 (0.49–1.64)

0.723

0.88 (0.48–1.61)

0.686

0.70 (0.38–1.27)

0.239

0.68 (0.38–1.25)

0.216

Latency (years)

 > 5 versus ≤ 5

0.002 (0–0.07)

0.001

0.002 (0–0.07)

0.001

1.89 (1.17–3.05)

0.009

1.85 (1.14–3.00)

0.012

Latency × Timec

1.08 (1.03–1.13)

0.001

1.08 (1.03–1.12)

0.001

–

–

–

–

  1. Bold means statistic significance
  2. BC breast cancer, TNM tumour node metastasis, SPM second primary malignancy
  3. aSurvival time from BC diagnosis
  4. bSurvival time from SPM diagnosis
  5. cLatency was transformed into a time-varying covariate to assess the survival time from BC diagnosis